## SYPHILIS IN SOUTH DAKOTA

### 2021 DATA  
Provisional data as of 3.1.22

<table>
<thead>
<tr>
<th>ADULT SYPHILIS</th>
<th>CONGENITAL / SYPHILITIC STILLBIRTHS</th>
</tr>
</thead>
<tbody>
<tr>
<td>874 Infections Reported</td>
<td>16 Congenital and 4 Syphilitic Stillbirths</td>
</tr>
<tr>
<td>622% Increase from 2020</td>
<td>300% Increase from 2020</td>
</tr>
<tr>
<td><strong>1,050%</strong> Increase from 5-Year Median</td>
<td><strong>700%</strong> Increase in 5-Year Median</td>
</tr>
</tbody>
</table>

---

**Reducing an Unprecedented Rise in Syphilis Rates by Enhanced Screening & Testing**
### RISK FACTORS:
- 93% heterosexual exposure
- 45% history of other STIs
- 45% history of incarceration
- 75% American Indian
- 59% Reported age range of 25-39 years-old
- 36% sex while intoxicated
- 27% used IV drug use
- 21% cases reported among an institutionalized population

The SD Department of Health asks providers to perform enhanced screenings in select settings and populations.

### SCREEN

#### PRENATAL CARE PROVIDERS
- All pregnant women should be screened for syphilis **three times** during pregnancy during this outbreak:
  - At first prenatal appointment or at time of initial pregnancy diagnosis if concerned for poor follow up
  - At 28 weeks
  - At delivery
- All pregnant women delivering a stillbirth (gestational age ≥20 weeks)

#### EMERGENCY DEPARTMENT / URGENT CARE PROVIDERS / PRIMARY CARE PROVIDERS
- All pregnant women
- Men who have sex with men
- Individuals with HIV infection
- Individuals with multiple sex partners, or a partner who has multiple sex partners
- Individuals incarcerated
- IV drug users and/or substance abuse
- Individuals with a history of sexually transmitted infections

In an effort to stop congenital syphilis **SD-DOH recommends enhancing syphilis screening to emergency room departments and urgent care.** In 2021 South Dakota mothers associated with congenital/syphilitic stillbirths had insufficient, late, or no prenatal care, however, some of those same women and/or their partners were seen in emergency rooms and urgent care for reasons other than prenatal care. Screening women of reproductive age (15-45 years) and sex partners to women of reproductive age can reduce congenital syphilis.

### PHYSICAL EXAMINATION
- If the history or serologic tests are suggestive **AND/OR**
- Sex or needle-sharing partner with symptoms of or infection with syphilis
  - Evaluate oral signs of syphilis, including mouth sores (chancres) or mucus patches, or rashes on the body, particularly on the palms of the hands or soles of the feet (a characteristic of syphilis infection that is unusual in other conditions) and to evaluate external genital, anal, or perianal sores (chancres) or other lesions (i.e., condyloma lata) to help determine the stage of syphilis.

### MEDICAL HISTORY
- Previous STI history & treatment
- Sexual partner with STIs
- Symptom history: Particularly symptom history of sores on the genitals, anus, or mouth or a rash on the body, especially on the palms of the hands or soles of the feet.
- Sexual orientation
- Number of sex partners
- Injection Drug Use
Immediately treat infected individuals, individuals with signs/ symptoms, and individuals who report exposure to syphilis, even before confirmatory test results return. Additionally, if tests are negative, but the clinician is suspicious of syphilis, the patient should be treated for syphilis.

### RISK CATEGORY
<table>
<thead>
<tr>
<th>RECOMMENDED REGIMEN</th>
<th>ALTERNATIVES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early (primary, secondary, or early latent)</strong></td>
<td>benzathine penicillin G 2.4 million units IM in a single dose</td>
</tr>
<tr>
<td><strong>Late Latent or unknown duration</strong></td>
<td>benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1-week intervals</td>
</tr>
<tr>
<td><strong>Neurosyphilis, ocular syphilis, and otosyphilis</strong></td>
<td>Aqueous crystalline penicillin G 18-24 million units per day, administered as 3-4 million units by IV every 4 hours or continuous infusion, for 10-14 days</td>
</tr>
<tr>
<td><strong>For children or congenital syphilis</strong></td>
<td>See STI Treatment Guidelines, 2021</td>
</tr>
</tbody>
</table>

The complete list of recommendations on treating syphilis and discussion of alternative therapy in people with penicillin allergy can be found in [STI Treatment Guidelines, 2021](#).

### POST EVALUATION
- People with primary or secondary syphilis should have clinical & serologic evaluation at 6 & 12 months after treatment.
- People with HIV infection should have a clinical and serological evaluation for treatment failure at 3, 6, 9, 12, and 24 months.
- People with latent syphilis should have quantitative nontreponemal serologic tests repeated at 6, 12, and 24 months.

### MANAGEMENT OF PARTNERS
Anyone who has had sexual contact with an individual with syphilis should be notified, examined clinically, receive syphilis serologic testing, and receive treatment based on the following:
- **Sexual contact to a patient with primary/secondary/early latent syphilis:**
  - If exposed ≤ 90 days of a diagnosed case, **CDC recommends presumptive treatment for early syphilis, even if serologic test results are negative**
  - If exposed ≥ 90 days of a diagnosed case, CDC recommends **presumptive treatment** if serologic test results are not immediately available, and follow-up is uncertain. If serologic tests are positive, treatment should be based on clinical and serologic evaluation and syphilis stage. If serologic tests are negative, no treatment is needed.
- **Sexual contact to a patient with unknown duration or late syphilis:**
  - Evaluation & presumptive treatment of contacts exposed within 12 months of first serologic evidence of infection, or re-infection in the case-patient
Diagnosis of syphilis requires the use of two tests: a nontreponemal and a treponemal test.

**Nontreponemal Antibody Test:** Detect antibodies not specifically directed against the *Treponema pallidum* bacteria. The body produces these antibodies when an individual has syphilis but may also be produced in several other conditions. The tests are highly sensitive, but since they are non-specific, false-positive results can be caused by, for example, IDU, pregnancy, Lyme disease, certain types of pneumonia, malaria, TB, or certain autoimmune disorders, including lupus. Nontreponemal tests include:

- **RPR** (Rapid Plasma Reagin): in addition to screening, this test is useful in monitoring treatment for syphilis. It may also be used to confirm the presence of an active infection when an initial examination for treponemal antibodies is positive. For this purpose, the level (titer) of the antibody is measured.
- **VDRL** (Venereal Disease Research Laboratory): in addition to blood, this test is primarily performed on CSF to help diagnose neurosyphilis.

**Treponemal Antibody Test:** Detect antibodies that specifically target *T. pallidum*. They are highly specific for syphilis, meaning other conditions are unlikely to cause a positive result. However, once a person is infected and these antibodies develop, they remain in the blood for life. Treponemal antibody tests include:

- **FTA-ABS** (Fluorescent treponemal antibody absorption): this test is useful after the first 3-4 weeks following exposure. In addition to blood testing, it can be used to measure antibodies to *T. pallidum* in the CSF to help diagnose neurosyphilis.
- **TP-PA** (*T. pallidum* particle agglutination assay): this test is sometimes performed instead of FTA-ABS because it is more specific and has fewer false positives.
- **MHA-TP** (Microhemagglutination assay): another confirmatory method; this test is used much less commonly.
- **IgG and IgM Enzyme Immunoassays ~ IgG** (SYPGN / Syphilis Total Antibody, Serum): is recommended for prenatal screening. Testing for IgM-class antibodies should not be performed during routine pregnancy screening unless clinically indicated.

**STAGES OF INFECTION AND CLINICAL DESCRIPTION**

- **Primary Syphilis:** Classically presents as a single painless ulcer or chancre at the site of infection but can also present with multiple, atypical, or painful lesions.
- **Secondary Syphilis:** Characterized by localized or diffuse mucocutaneous lesions (e.g., rash — such as non-pruritic macular, maculopapular, papular, or pustular lesions), often with generalized lymphadenopathy. Other signs can include mucous patches, condyloma lata, and alopecia. The primary ulcerative lesion may still be present.
- **Early Non-Primary and Non-Secondary Syphilis:** A person’s initial infection has occurred within the previous 12 months, and there are NO signs or symptoms of primary or secondary syphilis. May fall between primary and secondary, and after the secondary stage.
- **Unknown Duration or Late:** Person’s initial infection has occurred greater than 12 months previously or in which there is insufficient evidence to conclude that infection was acquired during the previous 12 months.

**SYPHILIS MANIFESTATION**

Neurosyphilis, ocular syphilis, and otosyphilis should be considered in the differential diagnosis of neurological, ocular, and other signs and symptoms among persons with HIV Infection.
Congenital: An infant or child (aged less than 2-years) may have signs such as hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice (nonviral hepatitis), pseudo paralysis, anemia, or edema (nephrotic syndrome and/or malnutrition). An older child may have stigmata (e.g., interstitial keratitis, nerve deafness, anterior bowing of shins, frontal bossing, mulberry molars, Hutchinson teeth, saddle nose, rhagades, or Clutton joints).

Syphilis Stillbirth: A fetal death that occurs after a 20-week gestation or when the fetus weighs greater than 500g and the mother had untreated or inadequately treated during pregnancy.

Adequate Treatment for Infected Case During Pregnancy

- Completion of a penicillin-based regimen, appropriate for stage of infection, initiated 30 or more days before delivery.
- Pregnant women MUST be treated with penicillin. If allergic, she must be desensitized and treated to stage of illness.

Incubation Period

- Primary: A chancre typically occurs about 3 weeks (range 10 to 90 days) after exposure and lasts 3 to 6 weeks.
- Secondary: 4 to 8 weeks after onset of the primary chancre.
- Neurologic, Ocular, or Otic: Manifestations can occur at any stage of syphilis.
- Late clinical: Manifestations (tertiary syphilis) generally occur after 15–30 years of untreated infection.

What do Disease Intervention Specialists do?

Case Management and Partner Notification

Disease Intervention Specialists (DIS) follow-up with and provide case management to all physician-diagnosed and/or suspect cases. Case management includes:

- Completing a medical chart review for necessary patient information; for example, diagnostic, demographic, clinical, and known risk history information.
- Conducting client interviews to obtain additional pertinent information, elicit contacts, provide partner notification and disease management for follow-up and prevention.
- Providing STI testing and treatment assistance, for example, arranging transportation.
- Communicating pertinent information that is learned through investigations with the medical provider to assist with the testing and treatment continuum of care.

Disease Intervention Specialist Contact Information

Contact your local DIS with syphilis questions or if you need assistance contacting a client for testing, treatment, and counseling for syphilis, HIV/AIDS, and other sexually transmitted infections.

<table>
<thead>
<tr>
<th>Aberdeen</th>
<th>Mobridge</th>
<th>Sioux Falls</th>
</tr>
</thead>
<tbody>
<tr>
<td>402 S. Main St.</td>
<td>210 East Grand Crossing, Suite A</td>
<td>4101 West 38th St., Suite 102</td>
</tr>
<tr>
<td>Aberdeen, SD 57401-4127</td>
<td>Mobridge, SD 57601</td>
<td>Sioux Falls, SD 57106</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pierre</th>
<th>Rapid City</th>
<th>Watertown</th>
</tr>
</thead>
<tbody>
<tr>
<td>740 E. Sioux, Suite 107</td>
<td>909 E. St. Patrick, Suite 10</td>
<td>2001 9th Ave, SW #500</td>
</tr>
<tr>
<td>Pierre, SD 57501-3395</td>
<td>Rapid City, SD 57701</td>
<td>Watertown, SD 57201-4038</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mitchell</th>
<th>Main office</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1420 North Main St.</td>
<td>Main office</td>
<td></td>
</tr>
<tr>
<td>Mitchell, SD 57301</td>
<td>Toll-Free: 800-592-1861</td>
<td></td>
</tr>
<tr>
<td>605-995-8051</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Additional Resources for Providers

**CDC 2021 STI Treatment Guidelines**
https://www.cdc.gov/std/treatment-guidelines/default.htm

- An updated STI Treatment Guidelines mobile app is in development and is expected to launch in the coming months. CDC has an interim, mobile-friendly solution – please visit https://www.cdc.gov/std/treatment-guidelines/default.htm for instructions on how to access it.
- Provider Resources, including wall charts and pocket guide, are available at: https://www.cdc.gov/std/treatment-guidelines/provider-resources.htm
- A recording of the STI guidelines informational webinar and questions and answers are available at: https://www.cdc.gov/std/treatment/default.htm

**STI CLINICAL CONSULTATION SERVICE**
https://www.stdccn.org/render/Public
The National Network of STI Clinical Prevention Training Centers offers a *clinical consultation service* intended for licensed healthcare professionals and STI program staff. Submit a clinical consult by going to the above link and entering your online consultation request.

**NATIONAL STI CURRICULUM**
https://www.cdc.gov/std/training/courses.htm

The *National STI Curriculum* is a free educational website from the University of Washington STI Prevention Training Center. This online modular learning experience addresses the epidemiology, pathogenesis, clinical manifestations, diagnosis, management, and prevention of STIs. It is continuously updated and integrates the most recent STI Treatment Guidelines. Free CME/CNE/CE available.

A Guide for Taking a Sexual History: This booklet guides how to discuss sexual health issues with patients. Available at https://www.cdc.gov/std/treatment/sexualhistory.htm

This publication was supported by Centers for Disease Control and Prevention (CDC) grant number, 6 NH25PS005161-03-04 as a part of an award totaling $1,000,000.00 with $0.00 state funding. The views expressed in this written material or publication do not necessarily reflect the official policies of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.